Randomized trials have established the efficacy of focal treatment (either stereotactic radiosurgery or conventional surgery) for single brain metastases. In the past. adjuvant whole brain radiation therapy (WBRT) was routinely given with focal therapy. Recently. the utility of adjuvant WBRT has been called into question. This paper examines the scientific evidence and the arguments. pro and con. concerning the use of adjuvant WBRT in association with stereotactic radiosurgery or conventional surgery.
During the last 15 years, substantial progress has been made in the treatment of metastatic brain tumors. The most significant advance was the demonstration that aggressive focal treatment of single metastases results in better local control of tumor and an increase in length of life. Randomized trials evaluating focal treatments were first done with conventional surgery (I, 2) and more recently with stereotactic radiosurgery (SRS) (3, 4) . These studies show that focal therapy plus whole brain radiation therapy (WBRT) is superior to WBRT alone in the treatment of single brain metastases.
In all of the randomized trials evaluating either surgery or SRS, WBRT was given as adjuvant therapy along with the experimental focal therapy. WBRT was also the sole treatment used in all of the control arms. The reason for this was that WBRT alone was the standard of care in the past for the treatment of all brain metastases. The experimental designs of the trials provided for patients (in both the control and experimental treatment arms) to receive the standard therapy (WBRT), and in so doing, did not subject the patients in either arm to treatment solely with an "unproven" focal therapy.
After studies showed that focal treatment plus WERT was effective, the question arose "Does WERT need to be given after successful focal therapy?" There are several reasons for eliminating WBRT. First, WBRT has adverse, long-term neuropsychological side effects. Second, there are also the costs and time commitment of the patient that must be considered. And finally, there is the possibility that WERT may simply not be needed at all. It is theoretically possible to remove single brain metastases by surgery totally or to control them with radiosurgery. Furthermore, neuroimaging has improved, and it may now be possible to detect reliably additional metastases that may be present and treat these with additional focal therapy. If these last two statements are true, then there would be little justification for adjuvant WBRT.
On the other hand, compelling reasons exist for giving adjuvant WBRT. As a practical matter, it is probably impossible to remove completely all metastases with conventional surgery, and radiosurgery does not completely control the tumors. In addition, neuroimaging may not have reached the point yet where we can be absolutely certain that all metastases are being treated, and therefore some type of additional treatment may be needed. Also, although WBRT does have side effects, these side effects may not be as severe or as common as was previously thought (see below). In addition, most patients with brain metastases have relatively limited overall survival times, and so the really serious long-term side effects are usually not an issue in their care.
To date, there has been only one randomized trial (5) investigating the use of adjuvant WBRT after focal therapy. This study, which was conducted at the University of Kentucky, examined the efficacy of WBRT after surgery for single brain metastases. In that study, 95 patients who had single brain metastases that were completely resected (as determined by postoperative MRI scans) were randomized to treatment with postoperative WBRT (50.4 Gy) or to observation with no further treatment of the brain metastasis (until recurrence). Recurrence of tumor anywhere in the brain was less frequent in the radiotherapy group than in the observation group (18% vs. 70%, P<O.OOI). Postoperative radiotherapy prevented brain recurrence at the site of the original metastasis (10% vs. 46%, P<O.OOI) and at other sites in the brain (14% vs, 37%, P<O.OI). As a result, patients in the radiotherapy group were less likely to die of neurologic causes than patients in the observation group (6 of 43 who died [14%] vs. 17 of39 [44%]; P=0.003). There was no significant difference between the two groups in overall length of survival (median 49 weeks in the WBRT group vs 43 weeks in the observation group, p=0.39) or the length of time that patients remained functionally independent.
Despite the fact that the randomized trial (5) was overwhelmingly positive for preventing recurrences and reducing death due to neurologic cause, this study has actually provoked controversy rather than settling the issue. Results of this trial have been used as reasons both to give and not to give adjuvant WBRT. The justification for not giving WBRT holds that since no survival difference was found in the trial, WBRT really adds nothing to the treatment. This interpretation fails on several counts. With regard to survival, there was actually an increase of II % in survival time in the WBRT group when compared with the observation group. The relative risk of improved survival with WBRT was 1.1. However, this was not a statistically significant difference. Since there was a statistically significant reduction in death due to neurologic causes, ultimately adjuvant WBRT must have had some positive impact on overall survival time. The estimated sample size required to detect a significant difference of II % in overall survival with adequate power would have been 1,005 patients per group or 2,010 patients total. For practical reasons, the study could not.be designed to have this large of a sample size
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and, therefore, was not designed to detect moderate differences in survival, even one as large as II %. Therefore, the trial was never designed to show a significant difference in survival and the fact that it did not is not surprising.
There is an even stronger reason for discounting the apparent lack of efficacy of postoperative WBRT with regard to length of survival. Recurrence of tumor in the brain was the primary endpoint of the randomized trial, and this endpoint was the only truly direct measure of the effects of adjuvant WBRT. Up until recurrence of tumor, the two treatment groups were distinct, and the patients in each had received the treatment assigned by randomization. However, at recurrence, no specific treatment was mandated by the study design, and as a result, patients received a variety of additional treatments. There was an extremely large crossover of the observation group to WBRT. Of the 32 patients in observation group who developed recurrent brain metastases, 28 patients got WBRT. Overall, that means that 61% (28 patients of 46 total) in the "no WBRT" observation arm were, in fact, treated ultimately with WBRT. For the purposes of length of survival and functional independence, the study was virtually a comparison of surgery plus immediate WBRT versus surgery plus delayed WBRT. This substantially diluted the effect of WBRT given immediately postoperatively because WBRT almost certainly improved the length of survival and functional independence in the observation group. Therefore, arguments based on the supposed lack of efficacy of (immediate) postoperative WBRT on survival and functional independence are based on a fundamental misunderstanding of the design, results and limits of the randomized trial.
It should be noted that there is a randomized trial underway to determine the effects of giving or not giving adjuvant WBRT in conjunction with stereotactic radiosurgery. This study is similar in design to the trial discussed above that evaluated the effects of WBRT after conventional surgery. It is extremely likely that this new study will have a result similar to that of the surgical trial and so will not resolve the issue. Furthermore, this study does not contain subtle neurocognitive measures as endpoints and is not going to address the critical quality of life issues (discussed below) that are at the heart of debate over adjuvant WBRT.
As will be seen, the true benefit provided by adjuvant WBRT is a very real improvement in quality of life. The randomized trial (5) assessing adjuvant WBRT following surgery clearly showed that WBRT prevents the recurrence of metastases and, therefore, substantially reduces the need for further treatment. The trade off is that the patient must suffer the consequences of WBRT. But what really are these consequences?
The strongest argument for eliminating adjuvant WBRT is that cranial irradiation appears to result in unacceptable, 5 3 Gy x 10 + Radiosensitizer long-term neuropsychological damage. There is little doubt that radiation does damage the central nervous system. However, most of the evidence for this in humans comes from study of the effects of radiation on children and (to lesser degree) on adult long-term survivors of malignant gliomas. These groups are not really comparable to adult patients with brain metastases. Children have developing nervous systems that are much more susceptible to radiation damage than adults. And adults with malignant primary brain tumors usually have diffusely infiltrating tumors and a substantially larger and more widespread intracranial tumor burden than patients with brain metastases. In addition, patients with malignant gliomas have almost always received much larger doses of cranial radiation and chemotherapy than have patients with brain metastases. All of these factors make it likely that the neuropsychological side effects of radiation are more severe and frequent in children and adults with primary brain tumors than they are in adults with brain metastases.
In fact, very little work has been done on the neurocognitive side effects of WBRT in patients with brain metastases. The frequency of dementia following WBRT is unknown, and what information does exist comes from small retrospective series. The most often quoted paper is a 1989 report by DeAnglis et ai. (6) that found the frequency of dementia to be II % at one year in patients with nonrecurrent brain metastases who were treated initially with WBRT. This I I % figure has become firmly established in the literature. However, close scrutiny of this study raises serious questions about its interpretation. The sample size was small and consisted of only 47 patients in all -and only 5 of those developed dementia. A closer examination of those 5 patients shows that they all received either abnormally high daily fractions of radiation (that are not in current use today) or were given radiation cell sensitizing agents (that may have increased the damage to normal tissue) (Table I) . Of the 15 patients in that study treated with "modern" fractionation schemes (less than 3.0 Gy per fraction), none (0%) had dementia at one year. So, if this study supports any conclusion at all, it is the unlikely one that patients treated with daily fraction sizes less than 3.0 Gy are not at any increased Unfortunately, the same cannot be said of the side effects of recurrence of brain metastases. Several recent studies have demonstrated that the recurrence of brain metastases has a profoundly negative effect on the neurocognitive functioning of patients. A study by Regine et al. (7) found that in 36 patients with brain metastases treated with SRS alone, 47% had recurrence of brain metastases and 71% of the recurrences were symptomatic. Significantly, 59% of the patients with recurrent tumors had associated neurological deficits that did not improve even with successful treatment of the recurrence. Another study by Regine et al. (8) showed that, at three months post-treatment, patients treated for brain metastases with WBRT had greater negative changes in their minimental status examinations with uncontrolled brain tumors than they did with controlled brain tumors (-6.3 points versus -0.5 points, p=0.02). Also relevant (but somewhat farther afield) was a study by Taylor et al. (9) that showed that, in patients with primary brain tumors at 12 months post-treatment, changes in minimental status examinations were worse in patients with uncontrolled tumors (-2.42 points) than in patients with controlled tumors (+0.076 points) (p=0.0046). All of the patients in this study had received large total doses of conventional radiation therapy. These studies all strongly suggest that uncontrolled brain tumors result in a substantial decrease in mental performance and that this reduction far outweighs any decrement seen with cranial radiation therapy. Therefore, the side effects of recurrent tumors are worse than the side effects of preventive treatment. This is an extremely strong argument for the use of adjuvant WBRT in association with focal therapy. risk of developing dementia. In any event, the frequency of long-term neuropsychological side effects of WBRT in adult brain metastases patients appears to have been overestimated and seems to be well within the acceptable range when modem fractionation schemes are employed.
In addition to the "lack of survival benefit" and "horrendous side effects" arguments discussed above, other reasons have been put' forward for not giving adjuvant WBRT. A common point of view is that WBRT is not necessary because it is possible to go ahead and let the patients develop a brain recurrence because these can then be treated successfully with stereotactic radiosurgery. However, the risk of recurrence is quite high in patients who do not receive adjuvant WBRT, ranging from 42 to 87% in retrospective studies (10) (11) (12) (13) . There is a 2-8 fold increase of the likelihood of undergoing salvage brain treatment in patients not treated with WBRT (Table II) . As discussed previously, the cost of brain recurrence, even if successfully treated, is high and negatively impacts quality of life and neurocognition. Even if it were possible to treat all recurrences successfully (and this has not been the case in retrospective series ,(10-13» the cost paid in quality of life for letting these recurrences happen when they can be prevented is unacceptably high. focal external beam radiation to the site of the original metastases treated by SRS and not to give WBRT. This would decrease the recurrence rate at the original site; however, the impact on the overall brain recurrence rate would be only moderate. In the randomized trial examining WBRT after surgery (5), 46% of patients who did not receive WBRT developed recurrences at the original site of the tumor; with WBRT, the recurrence rate was 'iO% at the original site. The study also found that, in the patients who did not receive WBRT, 37% of recurrent brain metastases occurred outside of the field of the original metastases. Therefore, giving focal radiation to the site of the original metastases (only) would not prevent these other types of "distant" brain metastases and the expected overall recurrence rate using only focal conventional radiotherapy to the original site (with SRS) would be about 50% (10% at original site plus 37% at distant brain sites). Giving focal radiation would seem only to increase the radiation related side effects without adequately reducing the overall recurrence rate and, as a result would not be an optimum treatment plan. For now, adjuvant WBRT with stereotactic radiosurgery (and conventional surgery) is clearly the treatment of choice based on the best current scientific evidence. There is no doubt that WBRT substantially reduces the recurrence of brain metastases. The side effects ofWBRT have been overstated in the past and are in the acceptable range. On the other hand, it is clear that the side effects of recurrent brain metastases are unacceptable and far outweigh any potential problems associated with WBRT. Therefore, adjuvant WBRT should be given in conjunction with SRS. An ounce of prevention really is worth a pound of cure.
A more reasonable idea involves giving something other than WBRT to the whole brain to try to prevent recurrences both at the original site and at additional "distant" sites in the brain. One possibility is to give systemic chemotherapy following SRS. While a logical approach, the practical aspects of this make it an idea whose time probably has not yet come. So far, there are really no chemotherapeutic agents that have been shown to be unequivocally effective in the brain for the most common kinds of tumors that produce metastases. Nevertheless, as new agents become available and experience with chemotherapy increases, this may be a viable approach that could offer a substitute for WBRT in the future. (13) Sneed 1999 (12) Patchell 1998 (5) Several retrospective studies (10) (11) (12) (13) have been published comparing patientstreated with SRS who receivedWBRTwith those who did not receive WBRT. These studies have generally shown that the recurrencerate is reducedby adjuvantWBRT but that length of survival is not increased. This is put forward as another argument for not giving WBRT. However, a closer look at these studies shows that, paradoxically, they may actually provide an argument in favor of giving WBRT. Since these were retrospectivestudies, treatment assignment was not randomized and patient selection bias very clearly entered into the decision for treatment. In all of these studies, the WBRT group contained many more poor prognosis patients including those with multiple metastases and other unfavorable factors. For example, in the latest and largest study,a multi-institutional series reported by Sneed et al. (13) , single brain metastases were present in 58% of the SRS alone group but only 33% of the SRS + WBRT group. In addition, the intracranial tumor burden (as measured by the median total target volume) was substantially higher in the WBRT treated patients than in the SRS alone group (5.6 m1 vs 4.3 mI) . And this was almost certainly an underestimate for the patients in the WBRT group because the volume given referred only to the SRStreated volume. There were many more multiple metastasesin the WBRT group that were not includedin the SRS volume. Despite these disadvantages, the median survival times in both groups were almost identical (8.2 months for SRS alone vs 8.6 months for SRS +WBRT). This was not the expected result given the difference in prognostic groups represented by the two treatment arms. It would have been expected that the WBRTarm should have done worse, but instead there was no difference. This suggests that WBRT improved survival and actually made a difference overall, a conclusion opposite to that drawn by the study's authors. The real lesson here is that nonrandomized, retrospective studies cannot be used to resolve the question because of the insurmountable problem of patient selection bias inherent in these types of studies. 
